No Results Found
Try adjusting your search to find what you’re looking for.
5/23/2023
Pluton Biosciences Raises $16.5M Series A led by Illumina Ventures and RA Capital
Led by Illumina Ventures and RA Capital to discover and deploy microbes that will fight climate change. Illumina Ventures’ Charles Lin, PhD, who has joined Pluton’s Board of Directors, expressed his excitement about the fund’s first AgBio investment, “In the past two decades, we have witnessed how genomics revolutionized the landscape of human diagnostics and therapeutics. We expect genomics to...
Read More
4/13/2023
Alamar Biosciences Prepping Proteomics Platform for 2024 Launch
Proteomics firm Alamar Biosciences is preparing its NULISA (NUcleic acid-Linked Immuno-Sandwich Assay) platform for an early-access release later this year and a broad commercial launch in 2024. The NULISA system is based on the proximity ligation assay (PLA) originally commercialized by Olink Bioscience, the forerunner of Olink. PLA uses pairs of antibodies attached to unique DNA sequences to...
Read More
12/05/2022
SonoThera™ Completes $60.75M Series A Funding for Ultrasound-Guided, Nonviral Gene Therapy Platform Development
SonoThera™, a biotechnology company dedicated to treating the root cause of human diseases through genetic therapy, announced completion of its $60.75M Series A financing round.
Read More
3/28/2022
Sherlock Biosciences Raises $80 Million in Series B Financing to Democratize At-Home Diagnostic Testing
Sherlock Biosciences, a company engineering biology to bring next-generation diagnostics to the point-of-need, today announced it has raised $80 million in a Series B financing. The round was led by Novalis LifeSciences and included new investors Illumina Ventures, Albany Capital and Catalio Capital Management, among others. They joined Northpond Ventures, Good Ventures, and other existing inve...
Read More